PV Reporter

06/25/2026

PV Reporter’s Resources page has been updated with expanded clinical information, practical patient education,
---> and the welcomed addition of the 2026 NCCN MPN guidelines.

The new NCCN guidelines add simplified "one-stop" sections, plain language explanations of complex science, and guided questions to bring to your healthcare team.

This page brings together trusted MPN resources to support patients, caregivers, and oncology professionals with diagnosis, treatment discussions, monitoring, and shared decision-making in polycythemia vera, ET and myelofibrosis.

Visit the updated resources page here:

Find trusted MPN patient resources—support groups, financial aid, clinical trials, and expert education for polycythemia vera, ET & myelofibrosis.

06/24/2026

New MPN research worth watching: scientists found that JAK2V617F-positive MPN cells may depend heavily on glucose transport through GLUT1 and GLUT3.

Blocking this pathway reduced cancer cell viability and colony growth in lab and patient-derived samples, suggesting a possible metabolic weakness in PV, ET, and MF biology.

--> Important note: this does not mean cutting sugar treats MPN. It points to a future research path for targeting how mutant cells fuel themselves.

Background Myeloproliferative neoplasms (MPN) comprise a heterogenous group of hematological malignancies that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Current therapeutic strategies rely on cytoreductive approaches that mitigate disease burden...

06/23/2026

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the si...

06/21/2026

Happy Father's Day to all the wonderful dads! Missing mine, 27 years ago...your memory is always in my heart. ❤️ Thanks for always being there for me...even when a rare "ass whipping" was coming! You made me the man I am today.

06/17/2026

Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera

Deciphera Pharmaceuticals, LLC, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), announced the...

06/14/2026

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

🎯 Incredible response:
In essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)

New Positive Data Showed INCA033989 Achieved Rapid, Robust & Sustained Clinical & Molecular Responses and Was Well Tolerated in Patients with MF & ET

06/12/2026

Exciting new data presented at the EHA 2026 Congress highlights CGT1145, a promising new drug that targets the root cause of rare blood cancers (MPNs) like a sniper rifle rather than a sledgehammer.

Unlike current treatments that can crush healthy cells, "preclinical data" from their EHA poster presentation shows this "smart" therapy successfully shrinks enlarged spleens and normalizes blood counts while sparing healthy tissue.

With an IND application planned for later this year to kickstart human trials, this breakthrough could offer a much safer, more effective option for patients in need.

https://finance.yahoo.com/sectors/healthcare/articles/cogent-biosciences-announces-preclinical-data-120100395.html

06/11/2026

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

https://silence-therapeutics.com/investors/press-releases/press-releases-details/2026/Silence-Therapeutics-Highlights-Follow-Up-Data-at-EHA-2026-Demonstrating-Durable-Efficacy-and-Potential-Best-in-Class-Profile-for-Divesiran-in-Polycythemia-Vera/default.aspx

06/09/2026

A lovely Tuesday afternoon enjoying a spirited cruise on Black Beauty. 😎 Keeping the mind clear, the spirit high, and enjoying the open road.

​Wishing all my fellow warriors a wonderful rest of the week. Happy Tuesday y'all!

06/05/2026

MPN Clinical Trial Finder (Update)

Free to use, no personal information required, and still the only tool of its kind, built specifically to serve our community.

I've been exploring different ways to make the Trial Finder more robust as it continues to develop. The newest feature is a "Clinical Trial Discussion Sheet" you can print and bring to your next doctor's appointment.

The sheet runs about 2 to 3 pages and includes a summary of the trial, the eligibility criteria, and contact & location information, everything your hematologist needs to talk it through with you.

Check out the screenshots in the comments below to see how to access it. And please drop a comment if you have ideas for features you'd find helpful, or if you run into any problems.
Thank you!

Search hundreds of MPN clinical trials with our free trial finder tool. Filter by PV, myelofibrosis, or ET, trial phase and more. No personal information needed.